The World Health Organization identifies headache disorders (Symptomatic at least once within the last year) among the most common disorders of the nervous system, affecting 50% of adults worldwide. Thirty percent affected reported having had a migraine in the last year. Moreover, 1.7 to 4% of adults worldwide experience headaches 15 or more days per month. If one experiences migraines on 8 out of those 15 headache days and these symptoms last more than 3 months, one could be diagnosed as having chronic, persistent migraines. Chronic migraines affect 1% of the population, or about 75,000,000 people across the globe. It is estimated that about 36,000,000 Americans suffer from migraines, but 1 to 3 people discuss this with a physician. Depression and anxiety often accompany migraines, so suffering extends beyond physical pain. The 2015 Global Burden of Disease study identified migraine as the third cause of disability in adults under the age of fifty.

​

How does Anesthetic IV Infusions Relieve Migraines?

Recent studies suggest the efficacy of anesthetic IV infusion Therapy in the treatment of chronic migraines. The IV infusion is an antagonist of NMDA-subtype glutamate receptors, which are thought to play a role in pain transmission.

The Anesthetic IV infusion is sometimes used as an alternative to opiate-based painkillers because it targets 

N-methyl-D-aspartate (NMDA) receptors in the brain, not opiate receptor sites.

 

Subjects with refractory migraines who were given infusion therapy reported a significant decrease in

pain on the VAS scale and the infusion therapy has placed some patient's migraines into remission. This yields promising outcomes for patients who have failed other migraine treatments.

​

Please refer to our FAQ Page for more information on IV Infusions HERE.